How the eye's light receptor rhodopsin works in health and inherited vision disorders
Phototransduction in health and disease
This project aims to explain how defects in rhodopsin, the eye's light-detecting protein, cause inherited conditions like retinitis pigmentosa and night blindness so future treatments can be developed.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11319211 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are working to understand the tiny molecular steps by which rhodopsin — the light receptor in rod cells — converts light into signals and keeps photoreceptors healthy. They will examine how specific gene changes make rhodopsin fold improperly and clump together or become abnormally active, using biochemical tests and structural analyses. The team plans to combine lab-based molecular experiments, 3D structural studies, and cell-based assays to link particular mutations to the ways they damage cells. Although this is laboratory-focused work rather than a treatment trial, the findings could point to targets for future medicines or better genetic counseling.
Who could benefit from this research
Good fit: People with inherited retinal disorders such as retinitis pigmentosa or congenital stationary night blindness, especially those known to carry rhodopsin (RHO) gene mutations, would be most relevant.
Not a fit: Patients with unrelated eye diseases or without rhodopsin mutations are unlikely to see direct benefit from this research.
Why it matters
Potential benefit: If successful, this work could clarify how specific mutations cause vision loss and identify molecular targets to guide future treatments for inherited retinal diseases.
How similar studies have performed: Rhodopsin and phototransduction have been extensively studied and structural advances exist, but the precise ways certain mutations cause disease remain incompletely understood, so this work builds on strong prior research while addressing novel gaps.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Park, Paul S — Case Western Reserve University
- Study coordinator: Park, Paul S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.